The first order from India consists of some 50 000 Foley catheters for infection protection (BIP Foleys) and generates direct sales revenues of close to 2 million SEK, at product delivery.

We are delighted that we can now start penetrating the Indian market for real. The problem of healthcare associated infections is huge, particularly in India, where the largest consumption of antibiotics in the world has led to a high level of multi-resistant bacteria. This means that there is an urgent need for preventive solutions, says Cecilia Edström, Director of Sales & New Business.

In parallel, the planned clinical study, involving 1 000 patients in total, has been initiated. The study will be conducted at six prestigious hospitals in different regions of the country and will be a powerful marketing tool in India.

This is information that Bactiguard Holding AB (publ) is required to publish in compliance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 9 December 2015, at 08.00.

For further information, please contact:
Ulrika Berglund, Head of External Affairs, mobile: 46 708 800 407